Table 1.
Fracture risk in postmenopausal women with a prevalent vertebral fracture*
| Fracture type | Placebo (%) | Alendronate (%) | Fracture risk (95% CI) |
|---|---|---|---|
| Morphometric ≥1 | 145 (15) | 78 (8) | 0.53 (0.41–0.68) |
| Morphometric ≥−2 | 47 (4.9) | 5 (0.5) | 0.10 (0.05–0.22) |
| Clinical vertebral | 50 (5.0) | 23 (2.3) | 0.45 (0.27–0.72) |
| Any clinical | 183 (18.2) | 139 (13.6) | 0.72 (0.58–0.90) |
| Any non-vertebral | 148 (14.7) | 122 (11.9) | 0.80 (0.63–1.01) |
| Hip | 22 (2.2) | 11 (1.1) | 0.49 (0.23–0.99) |
| Wrist | 41 (4.1) | 22 (2.2) | 0.52 (0.31–0.87) |
| Height loss (mm) | 9.3 | 6.1 | p<0.001 |
*
Note: Black et al 1996.
Abbreviations: CI, confidence interval.